上海赛默罗德生物科技

SimuRoad Biotechnology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for pain, cough, and other neurological disorders. The company utilizes a proprietary ion channel drug discovery platform to design highly selective small molecules targeting specific voltage-gated sodium channels and P2X receptors. Its lead program, SR419, is a selective Nav1.7 inhibitor currently undergoing Phase 2 clinical trials for various neuropathic pain conditions. SimuRoad aims to provide safer, non-opioid alternatives for patients suffering from chronic and acute pain through precision targeting of peripheral nervous system pathways.